Free Trial
NASDAQ:ME

23andMe (ME) Stock Price, News & Analysis

23andMe logo
$0.50 -0.27 (-35.32%)
Closing price 03/28/2025
Extended Trading
$0.50 0.00 (0.00%)
As of 03/28/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About 23andMe Stock (NASDAQ:ME)

Key Stats

Today's Range
$0.60
$1.10
50-Day Range
$0.50
$2.20
52-Week Range
$0.53
$12.76
Volume
29.28 million shs
Average Volume
1.25 million shs
Market Capitalization
$13.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

Receive ME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 23andMe and its competitors with MarketBeat's FREE daily newsletter.

ME Stock News Headlines

The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Judge OKs data privacy czar for 23andMe sale
23andMe (NASDAQ:ME) Stock Price Down 35.3% - Time to Sell?
See More Headlines

ME Stock Analysis - Frequently Asked Questions

23andMe's stock was trading at $3.25 at the start of the year. Since then, ME stock has decreased by 84.7% and is now trading at $0.4980.
View the best growth stocks for 2025 here
.

23andMe Holding Co. (NASDAQ:ME) issued its earnings results on Tuesday, January, 28th. The company reported ($1.02) EPS for the quarter. 23andMe had a negative net margin of 183.39% and a negative trailing twelve-month return on equity of 170.07%.

23andMe shares reverse split on Wednesday, October 16th 2024. The 1-20 reverse split was announced on Friday, October 11th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 15th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of ME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that 23andMe investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
1/28/2025
Today
5/06/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ME
Fax
N/A
Employees
770
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-666,700,000.00
Net Margins
-183.39%
Pretax Margin
-186.76%

Debt

Sales & Book Value

Annual Sales
$208.78 million
Cash Flow
$0.54 per share
Price / Cash Flow
0.93
Book Value
$2.34 per share
Price / Book
0.21

Miscellaneous

Free Float
19,766,000
Market Cap
$13.36 million
Optionable
Not Optionable
Beta
1.19
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:ME) was last updated on 5/6/2025 by MarketBeat.com Staff
From Our Partners